No Data
Meheco's Unit Gets European Union's Nod to Market Troxerutin Raw Drug Ingredient
China Pharmaceuticals: Report for the first quarter of 2025
2025 First Quarter Report
In the first quarter, China Meheco Group (600056.SH) reported a net income of 0.166 billion yuan, an increase of 14.27% year-on-year.
On April 29, Gelonghui reported that China Meheco Group (600056.SH) released its first quarter report, achieving a total operating income of 8.263 billion yuan in Q1 2025, a year-on-year decrease of 5.84%; the net income attributable to shareholders of the parent company was 0.166 billion yuan, an increase of 14.27% year-on-year; the basic EPS was 0.1112 yuan.
2024 Annual Report Summary
Full 2024 Annual Report
Investors One-year Losses Continue as China Meheco Group (SHSE:600056) Dips a Further 9.1% This Week, Earnings Continue to Decline
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
